Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01026987 · ClinicalTrials.gov registry record · Phase 1

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

A Phase 1 study, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target

NCT01026987: Completed Phase 1 study, sponsored by Washington University School of Medicine.

NCT01026987 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01026987, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target

Study Summary

Patients who have not had adequate blood count recovery post related or unrelated stem cell transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully improve their blood counts.

Primary Outcome

For recipients with ANC \< 500 or growth factor support dependent at study entry, Time to neutrophil improvement is measured from the date of CD34+ selected, T-Cell depleted infusion to the first of 3 consecutive measurements of neutrophil count \> 500/μl without growth factor support for \>7 days prior. RBC transfusion engraftment - independence from RBCs without growth factors.

Interventions

  • DRUG G-CSF
  • PROCEDURE Leukapheresis
  • DRUG AMD3100
  • PROCEDURE Stem Cell Infusion

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2010-04-29
Est. Completion 2016-06-08
Phase Phase 1

What the finished NCT01026987 record still lists

NCT01026987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).

The record links to 0 conditions, and to 4 interventions - of which G-CSF is the first listed.

NCT01026987 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01026987 about?

NCT01026987 is a clinical study titled "Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant". Patients who have not had adequate blood count recovery post related or unrelated stem cell transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully improve their blood counts.

What is the current status of trial NCT01026987?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2010-04-29. Estimated completion is 2016-06-08.

What interventions are being tested in trial NCT01026987?

The interventions under investigation include: G-CSF (DRUG), Leukapheresis (PROCEDURE), AMD3100 (DRUG), Stem Cell Infusion (PROCEDURE).

Who is sponsoring clinical trial NCT01026987?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01026987's enrollment target sits among peer trials

29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01026987, the US trial registry maintained by the National Library of Medicine. NCT01026987 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.